Early is Good specializes in ultra-sensitive multi-omics biomarker detection, aiming to revolutionize healthcare through advanced diagnostic technologies. Their platform enables simultaneous detection of various biomolecules, including DNAs, RNAs, proteins, and small molecules, with remarkable sensitivity down to attomolar levels (10^-18). This non-invasive approach utilizes urine and blood samples, significantly reducing assay time to under four hours without the need for complex extraction or amplification processes. The technology promises reproducibility with a coefficient of variation (CV) of less than 3%, making it a reliable option for clinical applications.

The company is actively developing products for oncology, including the BCDx Monitoring and BCDx Detect tests, which focus on bladder and prostate cancer. These tests aim to provide accurate, non-invasive monitoring and early detection, thereby improving patient outcomes and reducing the need for invasive procedures like cystoscopies. Early is Good's collaboration with the Mayo Clinic further underscores its commitment to advancing cancer diagnostics, with a focus on integrating their multi-omics platform into clinical practice for better decision-making in patient care.

United States

EIG's mission is to develop highly accurate and non-invasive multi-omic molecular testing solutions for complex diseases like cancer. The company has developed a Multi-omic Integration Platform that combines detection of DNA, RNA, protein and metabolite targets into a single assay. This breakthrough approach transforms the field of molecular diagnostics by offering unparalleled accuracy with comprehensive insights for early disease detection. www.earlyisgood.com.

Early is Good

Company Details